1 Bridging Study Evaluation - The Three-year Experience in Taiwan Center for Drug Evaluation Center for Drug Evaluation Yi-jin Chiou, Ph.D. Yi-jin Chiou,

Slides:

Advertisements

Similar presentations

The TB Alliance-Bayer Moxifloxacin Deal

Advertisements

The Drug Discovery Process

1 Case Studies in Modeling and Simulation Discussion Stella G. Machado, Ph.D. Office of Biostatistics/OTS/CDER/FDA FDA/Industry Workshop, September 2006.

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.

Implementation of Bridging Study-Taiwans Experience Meir-Chyun Tzou, Ph.D. Senior Officer, and Director of Section III, Bureau of Pharmaceutical Affairs.

Robert T. O’Neill, Ph.D. Director, Office of Biostatistics CDER, FDA

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

Development of Evaluation and Consultation on Bridging Studies: Thailand Experiences Suchart Chongprasert, Ph.D. Investigational New Drug Subdivision Food.

Use of Foreign Data for Approval Ann Farrell, MD Division of Oncology Drug Products Center for Drug Evaluation and Research Food and Drug Administration.

Improving Dementia Care and Reducing Unnecessary Use of Antipsychotic Medications in Nursing Homes Alice Bonner, PhD, RN Division of Nursing Homes Center.

FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.

Drug Development in Asia – an Industry perspective Stephen UdenPfizer Inc.

Many Important Issues Covered Current status of ICH E5 and implementation in individual Asian countries Implementation at a regional level (EU) and practical.

Pharmacogenetics: Global Regulatory Issues ASENT 13 th Annual Meeting Bethesda, MD February 26, 2011 Issam Zineh, PharmD, MPH Associate Director for Genomics.

QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: Fax:

1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

PK and PD Studies for Systemic Exposure of Locally Acting Drugs Industry View Lester I. Harrison, PhD Division Scientist 3m Pharmaceuticals.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.

Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

How and Why Drugs Work Chapter 5

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Points for Discussion Panelists: Drs.Iwasaki, Takahashi, Wood.

1 An Overview of Bridging Evaluations in Taiwan Chin-Fu Hsiao 1, Mey Wang 2, Herng-Der Chen 2, Yu-Yi Hsu 1 and Jen-pei Liu 3 1 Division of Biostatistics.

Richard D. Hockett, Jr. M.D. Sr. Clinical Research Physician Group Leader, Genomic Medicine FDA Clinical Pharmacology Advisory Committee Integrating Pharmacogenomics.

IF:Pain © PGXL Laboratories. Pain Management - Opioids Problem and Implications 2% to 40% of adults suffer from chronic pain 1 90% of patients.

1 銜接性試驗評估與藥動學之應用鮑力恒國防醫學院藥學系. 2 3 Extrinsic factors Intrinsic factors Race Gender Genetic Hepatic Disease Renal Disease Age ClimateMedical Practice.

Delivering Robust Outcomes from Multinational Clinical Trials: Principles and Strategies Andreas Sashegyi, PhD Eli Lilly and Company.

PHARMACOKINETICS 1. Fate of drugs in the body 1.1 absorption

Orientation to Pharmacology

PharmacogeneticsPharmacogenetics Dr, P Derakhshandeh, PhD Dr, P Derakhshandeh, PhD.

Risk Assessment Nov 7, 2008 Timbrell 3 rd Edn pp Casarett & Doull 7 th Edn Chapter 7 (pp )

EMEA London Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

UIPS Utrecht Institute for Pharmaceutical Sciences Priority Medicines for Europe and the World: Cross-cutting themes Hubert G. Leufkens.

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

1 Chapter 9 Bridging Studies & Multi-Regional Trials.

1 METHODS FOR DETERMINING SIMILARITY OF EXPOSURE-RESPONSE BETWEEN PEDIATRIC AND ADULT POPULATIONS Stella G. Machado, Ph.D. Quantitative Methods and Research.

Phase I Issues for Novel TB Drugs Dakshina M. Chilukuri, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics, FDA OPEN FORUM ON KEY ISSUES IN TB.

1 Chapter 9 Bridging Studies. 2 Outline  Introduction  Taiwan ’ s Situations  An Bayesian Approach  Discussion.

1. Fate of drugs in the body 1.1 absorption 1.2 distribution - volume of distribution 1.3 elimination - clearance 2. The half-life and its uses 3. Repeated.

Copyleft Clinical Trial Results. You Must Redistribute Slides The American College of Cardiology Foundation / American Heart Association Clopidogrel Recommendations.

Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.

Shirley M. Tsunoda Liver Transplant, Drug Metabolism/PK Research Interests Investigating the genetic and environmental factors that influence variability.

Pharmacogenetics.

Ameeta Parekh, Ph.D. CDER/OCPB CPSC Meeting November 17/18

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

Modified release products. Considerations in the evaluation of modified release products Requirements for preparing extended release products. The bioavailability.

Summary of Discussion. l Issues –Practical use of ICH E5 guideline –Simultaneous global drug development.

Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.

1 The Role of Exposure-Response Evaluation in Drug Development and Regulatory Decisions Case Study: Rosuvastatin Hae-Young Ahn, Ph.D. Office of Clinical.

Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.

PHT 415 BASIC PHARMACOKINETICS

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 Current Status of Dose Selection in Antimicrobial Drug Development.

Genotype-directed dosing for Efavirenz

ICH E17 General Principles for Planning and Design of MRCTs

Simone M. Shurland, Ph.D., Division of Anti-Infective Products

Risk Assessment Dec 7, 2009 Timbrell 3rd Edn pp 16-21

Pharmacogenomics Genes and Drugs.

Bioequivalence trials: design, evaluation, regulatory requirements

Therapeutic Drug Monitoring chapter 1 part 1

Introduction to Pharmacogenetics

Current Evaluation Process

Introduction to Research Methods in Psychology

Presentation transcript:

1 Bridging Study Evaluation - The Three-year Experience in Taiwan Center for Drug Evaluation Center for Drug Evaluation Yi-jin Chiou, Ph.D. Yi-jin Chiou, Ph.D. October 28, 2003 October 28, 2003

2 Regulatory Reform in Clinical Trials July 7 Announcement (1993): An approved study report of a local clinical trial is required for the new drug application in Taiwan Double 12 Announcement (2000): Bridging Studies *2001: BSE optional; BS optional if not waived *2003: BSE mandatory; BS optional if not waived *2004: BSE mandatory; BS only if not waived

3 Current Checklist for Assessing Ethnic Sensitivity PK/PD Properties 1. Linear or non-linear PK in therapeutic dose range 2. Steep or flat concentration-effect curve for efficacy and safety 3. Narrow or wide therapeutic dose range 4. Whether it is highly metabolized, especially via a single pathway 5. Whether it is metabolized by genetically polymorphic enzymes 6. Whether it is administered as a prodrug via variable enzymatic conversion 7. High or low inter-subject variation in bioavailability 8. High or low bioavailability Clinical Properties 1. Likelihood of use in a setting of multiple co-medications 2. Likelihood of inappropriate use 3. Different indications and/or epidemiology 4. Other factors of ethnic sensitivity (e.g. medical practice, culture, climate)

4 Results for BS Evaluation (I) (01/2001-8/2003)  Application － 74 cases  Case evaluated (62) 33 (53%) Asian data 29 (47%) No Asian data  BS waived (49)(79%) 26 (79%) 23 (79%) Asian data No Asian data

5  13 cases-bridging study not waived (21 %) Case #Asian dataPKPDEfficacySafetyExtrinsic factors 1Yes ★ 2 ★★ 3 ★★★★ 4 ★★ 5No ★ ★★ ★★ ★★ ★ 6Yes ★★ 7No ★★ 8 ★ ★★ ★ 9Yes ★★ ★★ ★ 10Yes ★★★ 11 Yes ★★★★ ★★ ★ 12No ★ 13No ★ 14Yes ★★★ 15Yes ★★ ★ Concerns of drug-drug interactions; ★ Concerns of dose adjustment

6  13 cases-bridging study not waived (21 %) Case #Asian dataReasons for not waiving BS 1YesPK studies not meeting regulatory requirement 2YesProposed dose and AE incidence higher in Asians 3NoNon-linear PK? ethnic difference in efficacy/safety? 4NoNon-linear PK; lack of Asian data; safety concern 5YesNon-linear PK; drug-drug interaction; dose concern; medical practice (antibiotics) 6YesEthnic difference in efficacy/safety? 7NoInsufficient dose-response data 8NoPotential drug-drug interaction (high CL); lack of Asian data 9YesInsufficient PK and efficacy/safety data; dose concern 10YesPK difference; lack of PD data; dose concern 11 YesDose concern; different medical practice/disease prevalence 12NoInsufficient PK data 13NoLack of Asian data; difference between Caucasian and Black 14YesDifferent PK between Caucasian/Japanese; insufficient Asian data; liver AE at high dose 15YesMetabolism unclear; PK higher than in Chinese; lack of dose- response; dose concern

7 Recommended Checklist for Assessing Ethinic Sensitivity PK/PD Properties 1. Linear or non-linear PK in therapeutic dose range 2. Steep or flat concentration-effect curve for efficacy and safety 3. Narrow or wide therapeutic dose range 4. Whether it is highly metabolized, especially via a single pathway 5. Whether it is metabolized by genetically polymorphic enzymes 6. Whether it is administered as a prodrug via variable enzymatic conversion 7. High or low inter-subject variation in bioavailability 8. High or low bioavailability Clinical Properties 1. Likelihood of use in a setting of multiple co-medications 2. Likelihood of inappropriate use 3. Whether notable hepatobiliary side effects exist 4. Whether clinically alarming drug resistance exists in the new region 5. Likelihood of higher incidence of an AE due to a different standard of care 6. Likelihood of poor tolerability because of major side effects 7. Administration by titration or fixed dose Lin et al. DIA 37: , , 2003